BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21768878)

  • 1. The number of lymphoma-associated macrophages in tumor tissue is an independent prognostic factor in patients with follicular lymphoma.
    Andjelic B; Mihaljevic B; Todorovic M; Bila J; Jakovic L; Jovanovic MP
    Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):41-6. PubMed ID: 21768878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
    Richendollar BG; Pohlman B; Elson P; Hsi ED
    Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma.
    Alvaro T; Lejeune M; Camacho FI; Salvadó MT; Sánchez L; García JF; Lopez C; Jaén J; Bosch R; Pons LE; Bellas C; Piris MA
    Haematologica; 2006 Dec; 91(12):1605-12. PubMed ID: 17145596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
    Canioni D; Salles G; Mounier N; Brousse N; Keuppens M; Morchhauser F; Lamy T; Sonet A; Rousselet MC; Foussard C; Xerri L
    J Clin Oncol; 2008 Jan; 26(3):440-6. PubMed ID: 18086798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
    Wahlin BE; Aggarwal M; Montes-Moreno S; Gonzalez LF; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
    Clin Cancer Res; 2010 Jan; 16(2):637-50. PubMed ID: 20068089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.
    Wahlin BE; Sander B; Christensson B; Kimby E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):388-97. PubMed ID: 17255259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
    Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
    Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
    Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.
    Alvaro T; Lejeune M; Salvadó MT; Lopez C; Jaén J; Bosch R; Pons LE
    J Clin Oncol; 2006 Dec; 24(34):5350-7. PubMed ID: 17135637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).
    Farinha P; Masoudi H; Skinnider BF; Shumansky K; Spinelli JJ; Gill K; Klasa R; Voss N; Connors JM; Gascoyne RD
    Blood; 2005 Sep; 106(6):2169-74. PubMed ID: 15933054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of tumor vascularization and microenvironment in follicular lymphoma].
    Nesterova ES; Kravchenko SK; Gemdzhian ÉG; Osmanov EA; Kovrigina AM
    Ter Arkh; 2013; 85(7):57-64. PubMed ID: 24137948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
    Kridel R; Xerri L; Gelas-Dore B; Tan K; Feugier P; Vawda A; Canioni D; Farinha P; Boussetta S; Moccia AA; Brice P; Chavez EA; Kyle AH; Scott DW; Sanders AD; Fabiani B; Slack GW; Minchinton AI; Haioun C; Connors JM; Sehn LH; Steidl C; Gascoyne RD; Salles G
    Clin Cancer Res; 2015 Aug; 21(15):3428-35. PubMed ID: 25869385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type.
    Wang H; Li P; Wang L; Xia Z; Huang H; Lu Y; Li Z
    Ann Hematol; 2015 Sep; 94(9):1535-44. PubMed ID: 25990795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
    Klapper W; Hoster E; Rölver L; Schrader C; Janssen D; Tiemann M; Bernd HW; Determann O; Hansmann ML; Möller P; Feller A; Stein H; Wacker HH; Dreyling M; Unterhalt M; Hiddemann W; Ott G;
    J Clin Oncol; 2007 Aug; 25(22):3330-6. PubMed ID: 17664481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.
    Xerri L; Bachy E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Brousse N; Rousselet MC; Foussard C; Brice P; Feugier P; Morschhauser F; Sonet A; Olive D; Salles G;
    Hum Pathol; 2014 Oct; 45(10):2085-93. PubMed ID: 25149549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival.
    Labidi SI; Ménétrier-Caux C; Chabaud S; Chassagne C; Sebban C; Gargi T; Biron P; Blay JY; Ghesquières H
    Ann Hematol; 2010 Jan; 89(1):25-33. PubMed ID: 19582455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
    Sweetenham JW; Goldman B; LeBlanc ML; Cook JR; Tubbs RR; Press OW; Maloney DG; Fisher RI; Rimsza LM; Braziel RM; Hsi ED
    Ann Oncol; 2010 Jun; 21(6):1196-1202. PubMed ID: 19875761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.